Human Neutrophil Peptide 1 vs Pexiganan — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?
Human Neutrophil Peptide 1 (HNP-1) is the most abundant alpha-defensin in human neutrophil granules, where it constitutes up to 30% of total protein content. Alpha-defensins HNP-1, -2, -3, and -4 are the human versions of the ancestral defensin family....
Calculate Human Neutrophil Peptide 1 dose →Pexiganan (MSI-78) is a synthetic analog of magainin-2, optimized for enhanced broad-spectrum antimicrobial activity and reduced hemolytic toxicity. It was developed by Magainin Pharmaceuticals (later Genaera) as a topical treatment for mildly infected diabetic foot ulcers....
Calculate Pexiganan dose →| Parameter | Human Neutrophil Peptide 1 | Pexiganan |
|---|---|---|
| Category | Antimicrobial Peptide | Antimicrobial Peptide |
| Research | Preclinical | Phase 3 (Failed 1999) |
| Half-Life | Hours (in tissues) | Hours (topical) |
| Typical Dose | N/A | 0.8% cream topically |
| Frequency | N/A | Twice daily |
| Route | Endogenous (secreted by neutrophils) / Research only | Topical cream |
| FDA Status | Not approved | Not approved (failed Phase 3) |
Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.
For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.